BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34384890)

  • 1. Statistical considerations of phase 3 umbrella trials allowing adding one treatment arm mid-trial.
    Ren Y; Li X; Chen C
    Contemp Clin Trials; 2021 Oct; 109():106538. PubMed ID: 34384890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.
    Park JJH; Siden E; Zoratti MJ; Dron L; Harari O; Singer J; Lester RT; Thorlund K; Mills EJ
    Trials; 2019 Sep; 20(1):572. PubMed ID: 31533793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats.
    Lee KM; Brown LC; Jaki T; Stallard N; Wason J
    Trials; 2021 Mar; 22(1):203. PubMed ID: 33691748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designs for adding a treatment arm to an ongoing clinical trial.
    Bennett M; Mander AP
    Trials; 2020 Mar; 21(1):251. PubMed ID: 32143729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials.
    Lu CC; Li XN; Broglio K; Bycott P; Jiang Q; Li X; McGlothlin A; Tian H; Ye J
    Ther Innov Regul Sci; 2021 Nov; 55(6):1145-1154. PubMed ID: 34160785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On model-based time trend adjustments in platform trials with non-concurrent controls.
    Bofill Roig M; Krotka P; Burman CF; Glimm E; Gold SM; Hees K; Jacko P; Koenig F; Magirr D; Mesenbrink P; Viele K; Posch M
    BMC Med Res Methodol; 2022 Aug; 22(1):228. PubMed ID: 35971069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal allocation strategies in platform trials with continuous endpoints.
    Bofill Roig M; Glimm E; Mielke T; Posch M
    Stat Methods Med Res; 2024 May; 33(5):858-874. PubMed ID: 38505941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.
    Meyer EL; Mesenbrink P; Dunger-Baldauf C; Fülle HJ; Glimm E; Li Y; Posch M; König F
    Clin Ther; 2020 Jul; 42(7):1330-1360. PubMed ID: 32622783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
    Love SB; Cafferty F; Snowdon C; Carty K; Savage J; Pallmann P; McParland L; Brown L; Masters L; Schiavone F; Hague D; Townsend S; Amos C; South A; Sturgeon K; Langley R; Maughan T; James N; Hall E; Kernaghan S; Bliss J; Turner N; Tutt A; Yap C; Firth C; Kong A; Mehanna H; Watts C; Hills R; Thomas I; Copland M; Bell S; Sebag-Montefiore D; Jones R; Parmar MKB; Sydes MR
    Trials; 2022 Sep; 23(1):757. PubMed ID: 36068599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some recommendations for multi-arm multi-stage trials.
    Wason J; Magirr D; Law M; Jaki T
    Stat Methods Med Res; 2016 Apr; 25(2):716-27. PubMed ID: 23242385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.
    Parmar MK; Sydes MR; Cafferty FH; Choodari-Oskooei B; Langley RE; Brown L; Phillips PP; Spears MR; Rowley S; Kaplan R; James ND; Maughan T; Paton N; Royston PJ
    Clin Trials; 2017 Oct; 14(5):451-461. PubMed ID: 28830236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer.
    Ventz S; Alexander BM; Parmigiani G; Gelber RD; Trippa L
    J Clin Oncol; 2017 Sep; 35(27):3160-3168. PubMed ID: 28530853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating non-concurrent controls in the analyses of late-entry experimental arms in multi-arm trials with a shared control group in the presence of parameter drift.
    Overbey JR; Cheung YK; Bagiella E
    Contemp Clin Trials; 2022 Dec; 123():106972. PubMed ID: 36307007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unlocking the Potential: A Systematic Review of Master Protocol in Pediatrics.
    Li Y; Nelson R; Izem R; Broglio K; Mundayat R; Gamalo M; Wen Y; Pan H; Sun H; Ye J
    Ther Innov Regul Sci; 2024 Jul; 58(4):634-644. PubMed ID: 38653950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials.
    Collignon O; Gartner C; Haidich AB; James Hemmings R; Hofner B; Pétavy F; Posch M; Rantell K; Roes K; Schiel A
    Clin Pharmacol Ther; 2020 May; 107(5):1059-1067. PubMed ID: 32017052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.
    Ventz S; Cellamare M; Parmigiani G; Trippa L
    Biostatistics; 2018 Apr; 19(2):199-215. PubMed ID: 29036330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
    Hague D; Townsend S; Masters L; Rauchenberger M; Van Looy N; Diaz-Montana C; Gannon M; James N; Maughan T; Parmar MKB; Brown L; Sydes MR;
    Trials; 2019 May; 20(1):294. PubMed ID: 31138292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
    Schiavone F; Bathia R; Letchemanan K; Masters L; Amos C; Bara A; Brown L; Gilson C; Pugh C; Atako N; Hudson F; Parmar M; Langley R; Kaplan RS; Parker C; Attard G; Clarke NW; Gillessen S; James ND; Maughan T; Sydes MR;
    Trials; 2019 May; 20(1):264. PubMed ID: 31138317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.